Related Experiment Videos
Pharmacokinetics of once-daily dosing of gentamicin in neonates
K C Hayani1, F K Hatzopoulos, A L Frank
1Department of Pediatric, University of Illinois, Chicago 60612-7324, USA.
Insights
Once-daily gentamicin therapy in neonates achieves higher peak serum levels for better bacterial killing. This dosing strategy may allow for larger doses and longer intervals in term neonates without increased toxicity.
Area of Science:
- Neonatal pharmacology
- Antibiotic dosing optimization
- Infectious disease management in neonates
Background:
- Gentamicin is a critical antibiotic for treating neonatal infections.
- Traditional dosing regimens may not achieve optimal therapeutic concentrations.
- Optimizing gentamicin dosing is essential for efficacy and safety in neonates.
Purpose of the Study:
- To compare the pharmacokinetic profiles of once-daily versus twice-daily gentamicin dosing in neonates.
- To evaluate the safety and efficacy of different gentamicin dosing frequencies.
- To determine if once-daily dosing can achieve superior peak serum concentrations for enhanced bacterial killing.
Main Methods:
- Prospective, randomized trial comparing once-daily (5.0 mg/kg) versus twice-daily (2.5 mg/kg) intravenous or intramuscular gentamicin.
- Study included 11 neonates in the once-daily group and 15 in the twice-daily group for 2-3 days.
- Key pharmacokinetic parameters measured included peak, 6-hour postdosing, and trough concentrations, elimination half-life, and volume of distribution.
Main Results:
- Once-daily dosing resulted in significantly higher mean steady-state peak concentrations (10.7 vs 6.6 µg/ml) and 6-hour postdosing concentrations (4.7 vs 2.8 µg/ml).
- Elimination half-life was longer with once-daily dosing (8.8 vs 5.4 hours), while trough concentrations were similar (1.7 vs 1.7 µg/ml).
- No nephrotoxic effects were observed in any treatment group, indicating a favorable safety profile.
Conclusions:
- Once-daily gentamicin therapy at 5.0 mg/kg in neonates yields peak serum levels more conducive to optimal bacterial killing compared to traditional regimens.
- The similar trough levels suggest potential for even larger doses and extended dosing intervals in term neonates.
- This optimized dosing strategy holds promise for improved gentamicin efficacy and safety in the neonatal population.
Abstract:
In a prospective, randomized trial of once-daily versus twice-daily intravenous or intramuscular dosing with gentamicin, 11 neonates received 5.0 mg/kg once daily and 15 received 2.5 mg/kg twice daily for 2 ro 3 days. The once-daily intravenous dosing group and the twice-daily intravenous or intramuscular dosing group, respectively, had mean steady-state gentamicin peak concentrations of 10.7 versus 6.6 micrograms/ml (p < 0.05), 6-hour postdosing concentrations of 4.7 versus 2.8 micrograms/ml (p < 0.05), trough concentrations of 1.7 versus 1.7 micrograms/ml, elimination half-life of 8.8 versus 5.4 hours (p < 0.05), and volume of distribution at steady state of 0.67 versus 0.46 L/kg. No nephrotoxic effects were identified in any group. Once-daily gentamicin therapy with 5.0 mg/kg in neonates achieves peak serum levels that are more suitable for optimal bacterial killing than those which traditional regimens achieve. Similar trough levels suggest that even larger doses and longer dosing intervals may be ideal in term neonates.